These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25620067)

  • 1. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.
    Poon C; He C; Liu D; Lu K; Lin W
    J Control Release; 2015 Mar; 201():90-9. PubMed ID: 25620067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
    Poon C; Duan X; Chan C; Han W; Lin W
    Mol Pharm; 2016 Nov; 13(11):3665-3675. PubMed ID: 27712076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
    Jiang X; Lee MJ; Luo T; Tillman L; Lin W
    Biomaterials; 2023 Oct; 301():122235. PubMed ID: 37441902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
    Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
    Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
    Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
    Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
    Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
    J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy.
    Liu D; Poon C; Lu K; He C; Lin W
    Nat Commun; 2014 Jun; 5():4182. PubMed ID: 24964370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
    Airoldi M; Cattel L; Passera R; Pedani F; Milla P; Zanon C
    Pancreas; 2006 Jan; 32(1):44-50. PubMed ID: 16340743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
    Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
    Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice.
    Moschidis A; Papageorgiou A; Atmatzidis K; Tsalis K; Moschidis E; Livanis J; Chrysogelou E; Mourelatos D; Tsavdaridis D; Harlaftis N
    Chemotherapy; 2007; 53(3):153-9. PubMed ID: 17347561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
    Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
    Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
    Banerjee S; Kaseb AO; Wang Z; Kong D; Mohammad M; Padhye S; Sarkar FH; Mohammad RM
    Cancer Res; 2009 Jul; 69(13):5575-83. PubMed ID: 19549912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
    Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.